trial

Comparing Antipsychotic Medications in LBD Over Time

NCTId NCT05590637
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Recruiting
Enrollment 94 (estimated)
Sponsored by The University of Texas Health Science Center at San Antonio
Primary completion 2026-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Recruiting
Enrollment
94 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2022-04-22
Primary completion
2026-08
Eligibility
ALL

Interventions & indications

Drugs
PimavanserinQuetiapine

Sponsors

The University of Texas Health Science Center at San AntonioLead Sponsor
Alzheimer's AssociationCollaborator

Investigators

1
Sarah Horn, MDPrincipal Investigator

Sites

2 total
San Antonio, United StatesSan Antonio, United States

Facts & assertions

4 sourced
Enrollment
94
Phase
PHASE4
Primary Completion Date
2026-08
Status
RECRUITING
relationships
The graph out of here
drug
Pimavanserin
drug
Quetiapine
drug
lead_sponsor
The University of Texas Health Science Center at San Antonio
company
collaborator
Alzheimer's Association
company
indication
Hallucinations
indication
Dementia With Lewy Bodies
indication
Lewy Body Disease
indication
investigator
Sarah Horn, MD
person